6 assets in Desmoid Tumor

Therapeutic assets addressing Desmoid Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Desmoid Tumor	Parabilis Medicines, Inc.	P2	B (62)
Ipilimumab Desmoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Fog-001 Desmoid Tumor	Parabilis Medicines, Inc.	P1/2	CCC (48)
Tegavivint Desmoid Tumor	Children's Oncology Group	P1/2	CCC (48)
Tipiracil Desmoid Tumor	Parabilis Medicines, Inc.	P1/2	CCC (48)
Trifluridine Desmoid Tumor	Parabilis Medicines, Inc.	P1/2	CCC (48)